Cargando…
Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors
Blocking interaction of the immune checkpoint receptor PD-1 with its ligand PD-L1 is associated with good clinical outcomes in a broad variety of malignancies. High levels of PD-L1 promote tumor growth by restraining CD8(+) T-cell responses against tumors. Limiting PD-L1 expression and function is t...
Autores principales: | Palsson-McDermott, Eva M., Dyck, Lydia, Zasłona, Zbigniew, Menon, Deepthi, McGettrick, Anne F., Mills, Kingston H. G., O’Neill, Luke A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646285/ https://www.ncbi.nlm.nih.gov/pubmed/29081778 http://dx.doi.org/10.3389/fimmu.2017.01300 |
Ejemplares similares
-
Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4(+) T Cell Pathogenicity and Suppresses Autoimmunity
por: Angiari, Stefano, et al.
Publicado: (2020) -
Bridging the gap—Immune cells that can repair nerves
por: McGettrick, Helen M.
Publicado: (2021) -
Pyruvate Kinase M2: A Potential Target for Regulating Inflammation
por: Alves-Filho, Jose C., et al.
Publicado: (2016) -
Targeting immunometabolism as an anti-inflammatory strategy
por: Pålsson-McDermott, Eva M., et al.
Publicado: (2020) -
Importance of validating antibody panels: Anti-PD-L1 clone binds AF700 fluorophore
por: Hughes, Michael J., et al.
Publicado: (2020)